Altogether 171 serum specimens from 58 patients with heterophil antibodypositive infectious mononucleosis were studied for antibody response to EpsteinBarr virus (EBV). The sera were tested for fluorescent immunoglobulin G (IgG) and IgM gel-precipitating (GP) and complement-fixing (CF) repeated serum specimens for up to 1 year after the onset of illness. The clinical picture of these patients was studied carefully and compared with the serological findings. Twenty-one of the patients had a pharyngeal and two had a glandular type of disease according to the classification of Klemola et al. (15) . The rest of the patients were chosen from the routine serum specimens sent to the
Epstein-Barr virus (EBV) is now, with good reason, considered to be the etiological agent of infectious mononucleosis (IM) (10) . The diagnosis of IM can be made, in most cases, from heterophil antibodies reacting in the Paul-Bunnel test or in the rapid slide tests. The heterophil antibody tests can, however, give falsepositive reactions in some cases (14) or remain negative (15, 20) . Especially children with EBV infections very often have negative reactions to heterophil antibodies, and the clinical picture is also usually atypical of IM. Fluorescent (immunoglobulin [Ig]G) antibodies are also known to develop very rapidly in EBV infections, and the rise in antibody titers is seldom detected (9, 21) . There are some reports of using the complement-fixing (CF) (24) and gel-precipitating (GP) antibodies in the diagnosis of recent infections with EBV (16) , but neither of these techniques used alone is sufficient for diagnostic use. Schmitz and Scherer (21) penicillin (100 U/ml); streptomycin (100 ug/ml); and kanamycin (200 zg/ml). Occasionally amfotericin B in a concentration of 2.4 gg/ml was included. After being cultivated at 35 C with 5% CO2 for 7 days, the cell concentration was adjusted from 106 to 1.5 x 106 cells/ml. The bottles were transferred to 32 C and kept without refeeding for 14 days before being used for slides as described elsewhere (13) . The P3HR-1 line was completely negative to direct IgG and IgM fluorescence but elicited a clear EBV-specific fluorescence in about 15 to 25% of the cells. This line has optimal EBV-specific IgG fluorescence in approximately 50 to 85% of the cells (12) .
Test procedure. The cell slides were overlaid by serum dilutions in the same way as for the determination of IgG antibodies to EBV, but the incubation of the cells with serum was performed in a moist chamber at 37 C for 3 h instead of 45 min. Schmitz and Scherer (21) (19) .
CF technique. The same antigen as in the GP assay also seemed to be useful in the CF antibody test. Sever's modified microtechnique (22) as described by Vihma (25) was used. Veronal-buffered saline with 0.1% gelatin was the diluent. The sera were heated at 56 C for 30 min, and the twofold dilutions of sera beginning from 1:5 were tested for CF reactivity with P3HR-1 antigen. The hemolytic system consisted of equal parts of 2% sheep erythrocytes and a dilution of hemolysin containing 2 full units. Four antigen units and about 1.6 units of complement were used in the test. After overnight incubation at +4 C, the hemolytic system was added and the plates were incubated at +37 C for 1 h. Then the plates were placed at +4 C for 1 to 2 h and read by visual estimation of the degree of hemolysis. The inhibition of hemolysis was recorded from 4+ to 0, and readings 4+ and 3+ were considered positive. Serum titers were expressed as the reciprocal of the highest serum dilution still giving VOL. 11, 1975 on November 1, 2017 by guest http://iai.asm.org/ Downloaded from NIKOSKELAINEN AND HANNINEN a positive reaction. Positive and negative sera from a patient with IM were included as controls in each test.
The control antigen for the CF test was made from human fetal fibroblasts in the same way as from P3HR-1 cells.
Determination of heterophil antibodies. The sheep erythrocyte agglutination technique with differential absorption (Paul-Bunnel) (3) was used to determine antibodies found in infectious mononucleosis.
Handling of the data. Exact details about the onset of illness given by the patients were available from all except four patients with a recent EBV infection. These four gave eight serum specimens, which are not included in the antibody curves.
The geometric mean titers used in the antibody curves were calculated from the logarithms of the respective titer values. The value 1 was chosen for titers 10 and 5.
RESULTS
Fluorescent IgG antibodies to EBV. All 58 patients with IM had fluorescent IgG antibodies to EBV, and these developed very rapidly. Only one patient had serum specimens taken so early that there was a lack of antibodies in the first specimen. Information about the day of onset of illness was available from 54 patients with IM. The IgG antibodies to EBV in their sera are shown in Fig. 1 . The curve represents the geometric mean titers, which remained fairly stable throughout the observation period. The titers rose so rapidly that only 13 patients (22%) had a significant fourfold or greater rise in titers in the paired serum specimens taken in the acute phase and 10 to 20 days later. A significant fall in titers was detected in only 3 patients (5.2%).
Fluorescent IgM antibodies to EBV. All 58 patients with IM had IgM antibodies to EBV. These also developed rapidly, and the titer was usually at maximal level even in the first specimen (Fig. 2) . Seven patients (12%) had a significant rise in IgM antibody titers in the serum pairs taken in the acute and convalescent phase. A significant fall in the titer of the paired serum specimens was noted in 11 patients (19%). The IgM antibodies to EBV disappeared very rapidly after the onset of illness, and after 12 weeks no patients had IgM antibodies to EBV.
GP antibodies to EBV. A seroconversion or a clear rise in GP antibodies was noted in sera from 33 patients (57%) with IM, and the GP titer was at maximal level even in the first specimen taken from 17 patients (29%). Altogether 50 patients (86%) had GP antibodies, and these developed slowly in most cases ( Fig. 3  and 4) . The GP antibodies kept rising for up to 10 weeks on the average, and none of the patients had a fall in GP antibody level. All patients who were observed for more than 12 weeks had GP antibodies (Fig. 5 ), but the patients with negative reactions were followed only up to maximum of 4.5 weeks after the onset of illness.
CF antibodies to EBV. The CF antibodies also developed slowly and the titer kept rising on the average for up to 10 weeks, the same as that of the GP antibodies (Fig. 6) . A seroconversion or a significant rise in CF titers was detected in 11 patients (19%), 4 of them (6.9%) having the rise in the paired serum specimens. The rise in CF titer was not significant or the titer was at the maximal level already in the first specimen taken from 30 patients (52%), and only one patient had a significant fall in CF antibodies during the observation period. Altogether 42 patients with infectious mononu- cleosis (72%) had CF antibodies and 16 (28%) had negative reactions. The latter patients were only observed for up to 6 weeks, except for one who had a negative reaction even more than a year later.
Heterophil antibodies. In consequence of selection of study patients, all had heterophil antibodies, which were demonstrable soon after the onset of illness. They also disappeared rapidly, but slightly slower than IgM antibodies to EBV (Fig. 7) antibodies and the heterophil antibodies. All the individual EBV antibody and heterophil antibody curves can be seen in Fig. 8 Comparison of the GP and CF antibodies. Both GP and CF antibodies developed slowly after the onset of illness. Eight patients (14%) had negative reactions to GP antibodies, but six of them had CF antibodies to EBV. Sixteen patients (28%) had negative reactions to CF antibodies, but 14 of them had GP antibodies to EBV. Only two patients had negative reactions to both CF and GP antibodies, but these patients were observed for only 3.5 weeks after the onset of illness.
Clinical picture and the antibody status. The 23 patients who were treated in the Department of Infectious Diseases, University of Turku, were studied carefully for the clinical signs of IM. These were typical in every patient. The peripheral blood smear, erythrocyte sedimentation rate, blood chemistry for detection of liver damage as well as the antistreptolysin 0 and antistaphylolysin titers, urinalysis, routine bacteriological cultures from throat, sputum (if available), feces, and urine, and the Mantoux reaction were checked. The patients with rising or falling EBV IgG antibody titers as well as those with exceptionally high EBV IgG and IgM titers were studied with special care. The antibody titers showed no correlation to the clinical symptoms and signs or to the clinical and bacteriological laboratory findings.
Control tests on the specificity of the serological assays for EBV antibodies: fluorescent IgG antibody technique. In some earlier studies of fluorescent IgG antibodies to EBV in sera from patients with systemic lupus erythematosus, the antinuclear antibodies have also been detectable with Burkitt cell antigen (4). These two types of antibodies have, nevertheless, been easily distinguishable. If antinuclear antibodies have been detected with the Burkitt cell antigen, a nuclear fluorescence has been observed in about 80% of the cells. The specific EBV fluorescence was detectable in only 1 to 3% of Silfere cells (Fig. 9 ) and in 15 to 30% of P3HR-1 cells (Fig. 10) . A serum with a positive reaction to fluorescent antinuclear antibodies at a titer of 1:1,280 tested with mouse liver antigen was also titrated with Silfere and P3HR-1 antigens for EBV IgG antibodies with the same conjugate as in the antinuclear antibody test. The serum had with both Burkitt cell antigens an antibody titer of 1:320 to EBV. The fluorescence was specific for EBV, and no nuclear fluorescence, typical of antinuclear antibodies, was noted.
Fluorescent IgM antibody technique. To study the EBV-specific IgM antibodies (Fig.  11) , three serum specimens were fractionated in sucrose gradient ultracentrifugation ( Table 1 ). The first serum had only IgG antibodies to EBV, the second contained IgG and IgM antibodies to EBV and also heterophil antibodies, and the third had IgG antibodies to EBV and rheumatoid factor and gave a false-positive IgM fluorescence (6) . After the sucrose gradient ultracentrifugation, 10 fractions were collected from each specimen and tested for fluorescent IgG and IgM antibodies to EBV, heterophil antibodies, and rheumatoid factor ( Table 1) The micro GP antibody technique using the crude P3HR-1 Burkitt cell antigen is also sensitive and suitable for routine diagnosis. There are, however, patients who remain negative towards GP antibodies, because the sensitivity is lower than with the indirect immunofluorescence technique. The slow development of GP antibodies also makes it possible to confirm the diagnosis later if the acute-phase serum specimen is missing. Some of the patients in this study could not be observed for more than a few weeks, during which time the GP antibodies had not yet developed. The same crude P3HR-1 antigen was used for determination of CF antibodies to EBV. The CF technique was not, however, as sensitive as the GP method, since 28% of the IM patients had negative reactions to CF as compared with 14% with negative reactions to GP antibodies. A similar observation about the sensitivity of these two tests has been made for human wart virus antibodies (18) . One explanation for this may be the nonreactivity of the IgM antibodies in the CF test but reactivity in the GP assay. This explanation will not, however, clarify the discrepancy between the GP and CF tests.
The most promising and useful of these tests in diagnosis of recent infections was the IgM antibody technique. All patients with a recent EBV infection according to other serological tests had IgM antibodies to EBV, but these disappeared very rapidly. The determination of IgM antibodies directly from the serum without fractionation was practical and suitable for routine use. The latex agglutination test for rheumatoid factor must, however, b, made on all positive sera in order to confirm the specificity of the IgM fluorescence. It is known that patients with heterophil antibody-positive IM can sometimes have transient rheumatoid factor (27), which can render the IgM test from the whole serum useless. In those cases the conventional sucrose gradient ultracentrifugation can be used because it seems to separate the EBV IgG rheumatoid factor complexes.' If then the fractions with or without latex agglutination indicate IgM fluorescence, a diagnosis of an EBV infection can be made. Absorption of the rheumatoid factor with heat-aggregated human gamma globulin also seemed to be a good method. This completely eliminated the falsepositive fluorescence as well as the latex agglutinating activity. This method may be more suitable for routine use than the sucrose gradient ultracentrifugation.
With the EBV IgM antibody technique, a diagnosis also can be made from only one serum specimen containing IgM antibodies to EBV. The rheumatoid factor must, however, be excluded. Shirodaria et al. (23) have recommended that all serum specimens being used for virus-specific IgM fluorescence be absorbed with aggregated human gamma globulin. The control material of this study, in which some sera with negative reactions to latex agglutination gave false-positive IgM fluorescence that was eliminated by gamma globulin absorption, provides evidence for this.
